half-year financials, page-29

kwad, not sure you can simply say because now sales figures are released and are flat, that it explains the 'cruelling' of the share price.
The delay in oxypatch I believe counts for a big chunk, followed by general speculative stock sentiment, followed by delayed Mr. Global deal and yes, you can add in poor sales figures.

So you're 'told you so', is in fact a self proclaimed misplaced prophecy.

The upside is that most of the SP inhibitors can be reversed. The pending question under discussion is whether Elixia can be one of those.

But I think you'll find that most people here are not here to invest in a cosmetics company.